DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/qg2jrk/brain_cancer_drug) has announced the addition of the "Brain Cancer Drug Pipeline Update" report to their offering.
Despite the heavy investment made into brain cancer research, primary brain cancer, with glioblastoma multiforme being the most aggressive and most common form, remains one of the most deadly diseases in the developed world. While primary brain tumors are relatively rare, the chances of survival for patients with the disease are very low, even with the best treatment options currently available.
There are today 323 companies plus partners developing 371 drugs targeting brain cancer in development. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 95 drugs. Brain Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 223 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer.
To date 216 out of the 216 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 55 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Drug Pipeline Update at a Glance
Investigators
Includes more than 323 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.
Note: You are able to sort and find drugs according to companies and partners from drop-down menus in the application. You may also sort and find drugs according to country of companies.
Drug name & Synonyms
Lists commercial, generic and code names for drugs.
Developmental stage
This Drug Pipeline Update contains 371 drugs in development for the treatment of brain cancer. In addition there are suspended and ceased drugs.
Pipeline Breakdown According to Number of Drugs
- Marketed - 14
- Registered - 1
- Pre-registration - 1
- Phase III - 15
- Phase II - 144
- Phase I - 69
- Preclinical - 108
- No Data - 19
- Suspended - 2
-
Ceased - 95
For more information visit http://www.researchandmarkets.com/research/qg2jrk/brain_cancer_drug
